Research programme: neuropathic pain therapy - D-PharmAlternative Names: DP-236
Latest Information Update: 08 Nov 2006
At a glance
- Originator D-Pharm
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Neuropathic pain
Most Recent Events
- 27 Sep 2006 Discontinued - Preclinical for Neuropathic pain in Israel (unspecified route)
- 03 Jun 2005 Preclinical trials in Neuropathic pain in Israel (unspecified route)